Novavax Inc. has submitted an application to Switzerland’s drugs regulator for the authorization of its COVID-19 vaccine in adults, the U.S. vaccine maker said on Monday.
The submission is based on data from two key clinical trials in the United States and Mexico as well as in the UK that showed the vaccine was 90 percent effective against COVID-19.
Novavax’s protein-based vaccine is being reviewed by the U.S. Food and Drug Administration and has received approvals from the European Union and the World Health Organization.
It has also been cleared for use in adults in countries including the UK, New Zealand, and Australia. The company last week said its vaccine was about 80 percent effective in a late-stage trial in adolescents.
